Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VCEL mentioned FIRST in research report
ALBANY, New York, January 4, 2017 /PRNewswire/ --
The leading players operating in the Global Autologous Cell Therapy Market are Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc. These companies are expected to focus on mergers and acquisitions to enter local markets, observes Transparency Market Research. Furthermore, efforts to establish subsidiaries and manufacturing centers in emerging economies are also expected to make the global market exceptionally competitive in the coming few years.
According to the research report, the global autologous cell therapy market is expected to be worth US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.
http://www.prnewswire.com/news-releases/global-autologous-cell-therapy-market-development-of-bone-marrow-based-products-ensures-whopping-219-cagr-by-2024-observes-tmr-609627045.html
VCEL
Interesting to read the Q&A from this Takeda/AAstrom now VCEL, article
http://seekingalpha.com/article/1228921-is-takeda-interested-in-aastrom-bio
Is Takeda Interested In Aastrom Bio?
Feb. 27, 2013 9:57 AM ET
|
20 comments
|
PropThink
Follow (1,749 followers)
By Jason Napodano, CFA
What did the FDA approve? That's what is all about. Like lasers says, know what you own.
Please address those questions to lasers. There is information in the Intro, and/or ibox, seek and you shall find, if not, do what I do, yell "Help" to lasers.
hurley. vcel uses what material for its scaffolding? Is it porcine tissue?
Some recently older studies
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=36631914
Aastrom Biosciences | Open Studies| Completed
ClinicalTrials.gov
Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Condition: Alveolar Bone Defects
Interventions: Biological: Tissue Repair Cell therapy; Device: Tissue Repair Cells (TRC)
Sponsors: University of Michigan; Aastrom Biosciences
Phases: Phase I / Phase II
Number Enrolled: 24
Funded By: OTHER / INDUSTRY
NCT ID: NCT00755911
Completion Date: March 2010
Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.
Conditions: Fracture, Ununited; Pseudarthrosis
Interventions: Procedure: Fracture surgery; Drug: Cultured Bone Marrow Tissue
Sponsor: Aastrom Biosciences
Phases: Phase I / Phase II
Number Enrolled: 36
Funded By: INDUSTRY
NCT ID: NCT00424567
Completion Date: June 2007
Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion
Condition: Single Level Posterolateral Spinal Fusion
Interventions: Procedure: Bone Repair Cells (BRCs) with allogeneic, demineralized bone matrix; Procedure: Spine fusion with autologous bone graft
Sponsor: Aastrom Biosciences
Phases: Phase I / Phase II
Number Enrolled: 2
Funded By: INDUSTRY
NCT ID: NCT00797550
Completion Date: October 2008
Use of Vascular Repair Cells (VRC) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
Condition: Peripheral Arterial Disease
Interventions: Biological: autologous bone marrow cells; Biological: electrolyte solution (without cells)
Sponsor: Aastrom Biosciences
Phase: Phase II
Number Enrolled: 150
Funded By: INDUSTRY
NCT ID: NCT00468000
Completion Date: June 2011
Cardiac Repair Cell (CRC) Treatment of Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
Condition: Dilated Cardiomyopathy
Intervention: Biological: Cardiac Repair Cells (CRCs)
Sponsor: Aastrom Biosciences
Phase: Phase II
Number Enrolled: 40
Funded By: INDUSTRY
NCT ID: NCT00765518
Completion Date: June 2010
UPDATE: Tuesday March 3, 2009,
FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial
“… patient enrollment would resume in all four clinical sites and expects to complete it by the end of the year.
Activation of the fifth clinical site is underway.”
Bone Repair Cell (BRC) Treatment of Patients With Osteonecrosis of the Femoral Head
Condition: Osteonecrosis
Intervention: Procedure: Core decompression
Sponsor: Aastrom Biosciences
Phase: Phase III
Number Enrolled: 120
Funded By: INDUSTRY
NCT ID: NCT00505219
Completion Date: June 2011
updated Intro to VCEL added lasers find and some cc links, will be updating Ixmyelocel-T cranial updates tomorrow
too simple
You may find your answer in this Conference Call
http://edge.media-server.com/m/p/c6n8umpi
Next short interest reported Jan 25, 2017 after the bell
http://www.nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
This is the video on how the Carticel was done, that is being discontinued from US markets now that MACI is FDA approved.
Article on MACI from workmanscomp site dated 12-28-2016
http://www.workerscompensation.com/compnewsnetwork/news/25181-new-maci-knee-cartilage-surgery-shortens-rtw-time.html
Video on MACI dated Jan 12, 2017, Less Invasive compared to the youtube video in the ibox, the video in the ibox is crazy compared to this MACI video 1 minute 13 seconds of video shows how less invasive it is.
http://wnyt.com/health/maci-new-procedure-to-repair-damaged-knee-cartilage/4369510/
Updated VCEL company slide presentation, click the right/left arrows
http://www.vericelinfo.com/books/uwlr/#p=1
New site
but still under construction, added to ibox
http://www.maci.com/
Gut feeling says we get boomer news within 3 weeks and we fly.
I added some yesterday.
If VCEL was to get a buy out, lets say, what is a reasonable price and when?
It is estimated that the 9 biggest pharma and biotech companies hold over $120 billion in cash overseas, with Amgen (NASDAQ:AMGN) holding $35 billion, Gilead (NASDAQ:GILD) $25 billion, and Merck (NYSE:MRK) $20 billion. Many others are equally eager to use their cash, including Johnson & Johnson (NYSE:JNJ), Sanofi (NYSE:SNY), and Allergan (NYSE:AGN), which has been active with acquisitions in 2016 as well.
SA Article on bios for 2017, you must be signed up to read SA
http://seekingalpha.com/article/4035181-biotechnology-2017-bonanza-year?page=2
ibox, and over 250 patents and patent applications of Sanofi and certain of its subsidiaries
VCEL should expand on that
Is anyone else seeing MJ cannabis Ads on Ihub, yahoo, cnbc and other sites ruling, or is it just me?
I still think ceo of FLCR should have in the hopper a MJ merger, and we go to dollar land in 10 days on such a low A/S and O/S,
All the ceo has to do is amend the A/S to 700M and keep us flcr'ers pat with an anti dilution clause and give the new company 500M for coming on board, ,Providing they are accredited, of course.
We will be at pps .50 to .75 or $1.00 in 10 trading days and everyone will be millionaires
C'mon, wake up, WE ARE A FULLY REPORTING OTC BB filing company
Get with the times and market this company in a 50x of what it is worth.
JMHO
FLCR is a fully reporting OTC BB company, How often do you come across that, and has Assets and Years of Revenue.
I am also following the DD on twitter and other forums.
FLCR has a new moderator, awesome, in touch with the company.
ALL LOOKING GOOD.
FLCR, bring on some news.
Thank you, and forgive me for beefing in the last few weeks.
I am now curious as to what is going on with Ixmyelocel-T on the cranial studies. I just stumbled on that tonight while trying to build the ibox and doing DD
Holy mackerel this could be a ZINGER if they are still working on this.
And by the way you got to be a scientist to build the ibox, that is hard, got over 7 hours into it.
This will be another very important area to see in the up coming form 10-KSB in mid March
this topic
Employee Stock Purchase Plan
Employees are able to purchase stock under the Vericel Corporation Employee Stock Purchase Plan (ESPP), which was implemented effective October 1, 2015. Participation in this plan is available to substantially all employees. Compensation expense is recorded based on the fair market value of the purchase options at the grant date, which corresponds to the first day of each purchase period and is amortized over the purchase period. On October 3, 2016, employees purchased 62,000 shares resulting in proceeds from the sale of common stock of $0.1 million under the ESPP. The total share-based compensation expense for the ESPP for the three and nine months ended September 30, 2016 was less than $0.1 million and $0.2 million , respectively.
page 11
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11672588&RcvdDate=11/7/2016&CoName=VERICEL%20CORP&FormType=10-Q&View=html
lasers, Is this still something we are waiting for? Could be cool if a POSITIVE publishing of results come to a theatre near us.
Check out the ibox, Am I violating any rules with the Genzyme/Sanofi picture in the box WITH EXPLANATON AND LINK
If anything needs correcting, please let me know.
lasers, Did we ever hear anything on this topic
We also have an ixmyelocel-T investigator-initiated clinical study for the treatment of craniofacial reconstruction, for which we expect results by the first half of 2016, and we have conducted clinical studies for the treatment of CLI.
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11256239&RcvdDate=3/14/2016&CoName=VERICEL%20CORP&FormType=10-K&View=html
PAGE 10, TOP SENTENCE
Heart Failure Due to Dilated Cardiomyopathy
Suggest you wait for the 10-KSB to come out in mid March and any events in between now and then, jmho
Nasdaq site should be updated by then on institutional ownership as of 12-31-2016, maybe it will surprise us.
Never the less, good luck
One press release/8-K and we could be in a very different pps land.
Added to ibox, or also called Intro, again thank you for sharing
Thank you for posting that, I already printed it and will be showing it to some folks tomorrow in the professional sector.
Not me, I am adding more shares to my position. This is the first FDA approved stem cell company and even though we got hooked on the FDA roll, I am still going to add to my position.
My gut says double digit share price soon or by at least, year end. JMHO
3 to 5 years this should be a 50 to 100 dollar stock. Especially if Ixmyelocel-T gains traction.
FLCR How come stocktwits has no FLCR thread, That I looked for yesterday, twitter, I will check it out and am familiar with it.
Thank you, awesome.
70 followers, we should get up to over 400 on the BO, going to get fricken exciting, if multi penny's are coming
FLCR 6 million Assets and 1 Million in Revenues, gotta love a buyout coming, for a fully reporting OTCBB
http://data.cnbc.com/quotes/flcr
sheepwolf, what other forums are discussing FLCR ?
I agree, but its time to bury the old bones and move forward. Lets wait for the http://www.nasdaq.com/symbol/vcel/institutional-holdings to update and then we can see what happened
I am thinking we should edge up past $5's by mid March when the10K is due, unless we get some nice pr's till then
That is my target, over $5 by March 14, and then over $10 by Dec 31, 2017
5 and dime
Unless we get some Ixmyelocel-T partnership news and all bets are adjusted for 2x the above statement.
gail, are you calling for over a penny close, or openers on Tuesday?
Hope we get some 10-20 million volume days going forward and especially when News comes out.
If there are any signs of Baker Brothers adding VCEL to their holdings in the future, that will be all I will need for conviction.
Although I have 99.9% conviction now, just got a tid bummed at the manipulation that occurred on FDA approval.
But it will self correct this year as revenues build. IMHO
No, I think VCEL management is the most TOP NOTCH as they come.
I do not hold VCEL mgmt accountable for what occurred, IMHO, something else occurred outside their reach.
pgh maulers, I am long anyways, 3 to 5 years
I am going to try to add about up to 10k shares in the coming month, depends on my cash flow.
I still think double digits by year end or earlier. gl
Does anyone know when this specific site gets updated?
http://www.nasdaq.com/symbol/vcel/institutional-holdings
I didn't see any link as to when this gets updated? This should be a major tell-tale as to what happened as of 12-31-2016 and weeks prior
Also AKAO bolted from $5 to $18 with on only 31M revs and a similar share structure, but maybe the BAKER BROTHERS had something to do with that
http://data.cnbc.com/quotes/akao
NEVER THE LESS, I AM GOING TO ACCUMULATE AT THESE CURRENT PRICES.
LONG TERM, CAN'T GO WRONG.